Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies

Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ophthalmology 2018-01, Vol.2018 (2018), p.1-9
Main Authors: Lu, Chengxing, Metzig, Carola, Katz, Todd A., Gillies, Mark, Midena, Edoardo, Ogura, Yuichiro
Format: Article
Language:English
Subjects:
Age
Care and treatment
Clinical Study
Comparative analysis
Diabetes
Diabetic retinopathy
Lasers
Macular degeneration
Patient outcomes
Patients
Studies
Type 2 diabetes
Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c635t-e47c136249efa9bf4acb27881a3fab51178f6be7243b7d6f910e1bcb39e59233
cites cdi_FETCH-LOGICAL-c635t-e47c136249efa9bf4acb27881a3fab51178f6be7243b7d6f910e1bcb39e59233
container_end_page 9
container_issue 2018
container_start_page 1
container_title Journal of ophthalmology
container_volume 2018
creator Lu, Chengxing
Metzig, Carola
Katz, Todd A.
Gillies, Mark
Midena, Edoardo
Ogura, Yuichiro
description Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT 
doi_str_mv 10.1155/2018/3640135
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_49f10e630ebc4907adbab54e4c2a2b2a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A590650997</galeid><doaj_id>oai_doaj_org_article_49f10e630ebc4907adbab54e4c2a2b2a</doaj_id><sourcerecordid>A590650997</sourcerecordid><originalsourceid>FETCH-LOGICAL-c635t-e47c136249efa9bf4acb27881a3fab51178f6be7243b7d6f910e1bcb39e59233</originalsourceid><addsrcrecordid>eNqNks1v0zAYxiMEYlPZjTOKhISQoJu_HV-QSjeg0tAkVk3cLMd507gk9ogTEP897lq6FXHAPvjr9z62Hz1Z9hyjU4w5PyMIF2dUMIQpf5QdE6TQFCFePN7P2dej7CTGNUqNYsY5epodESULThE-zvSiuzV2yEOdvzcRWuchn4MfetPmX2BwPo3LxtlvHmLMg8-vxsGGDmLufD40kN8sbhbn0_PPF7nxVVpdL2d3q-thrBzEZ9mT2rQRTnbjJFt-uFjOP00vrz4u5rPLqRWUD1Ng0mIqCFNQG1XWzNiSyKLAhtam5BjLohYlSMJoKStRK4wAl7akCrgilE6yxVa2Cmatb3vXmf6XDsbpu43Qr7TpB2db0EzVqVhQBKVlCklTlekGBswSQ0pikta7rdbtWHZQ2a0bB6KHJ941ehV-aF4oQdILJ9nrnUAfvo8QB925aKFtjYcwRk0QI5IpkR4-yV7-ha7D2CfTE8WQFCxJsntqZdIHnK9DutduRPWMKyQ4Ukom6vQfVOoVdM4GD7VL-wcFrx4UNGDaoYmhHQcXfDwE325B24cYe6j3ZmCkNznUmxzqXQ4T_uKhgXv4T-oS8GYLNM5X5qf7TzlITIrHPY2TOVLQ37KI6kY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407648964</pqid></control><display><type>article</type><title>Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>PubMed Central</source><creator>Lu, Chengxing ; Metzig, Carola ; Katz, Todd A. ; Gillies, Mark ; Midena, Edoardo ; Ogura, Yuichiro</creator><contributor>Toto, Lisa ; Lisa Toto</contributor><creatorcontrib>Lu, Chengxing ; Metzig, Carola ; Katz, Todd A. ; Gillies, Mark ; Midena, Edoardo ; Ogura, Yuichiro ; Toto, Lisa ; Lisa Toto</creatorcontrib><description>Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT &lt; 400 μm and ≥400 μm. Results. At weeks 52 and 100, outcomes with intravitreal aflibercept 2q4 and 2q8 were superior to those in laser control-treated patients regardless of baseline CRT. When looked at in a binary fashion, the treatment effect of intravitreal aflibercept versus laser was not significantly better in the ≥400 μm than the &lt;400 μm group; when looked at as a continuous variable, baseline CRT seemed to have an impact on the treatment effect of intravitreal aflibercept versus laser. Conclusions. Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT &lt; 400 μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440.</description><identifier>ISSN: 2090-004X</identifier><identifier>EISSN: 2090-0058</identifier><identifier>DOI: 10.1155/2018/3640135</identifier><identifier>PMID: 29785301</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Age ; Care and treatment ; Clinical Study ; Comparative analysis ; Diabetes ; Diabetic retinopathy ; Lasers ; Macular degeneration ; Patient outcomes ; Patients ; Studies ; Type 2 diabetes ; Values</subject><ispartof>Journal of ophthalmology, 2018-01, Vol.2018 (2018), p.1-9</ispartof><rights>Copyright © 2018 Edoardo Midena et al.</rights><rights>COPYRIGHT 2018 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2018 Edoardo Midena et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2018 Edoardo Midena et al. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c635t-e47c136249efa9bf4acb27881a3fab51178f6be7243b7d6f910e1bcb39e59233</citedby><cites>FETCH-LOGICAL-c635t-e47c136249efa9bf4acb27881a3fab51178f6be7243b7d6f910e1bcb39e59233</cites><orcidid>0000-0003-3132-6233</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2407648964/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2407648964?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792,74897</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29785301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Toto, Lisa</contributor><contributor>Lisa Toto</contributor><creatorcontrib>Lu, Chengxing</creatorcontrib><creatorcontrib>Metzig, Carola</creatorcontrib><creatorcontrib>Katz, Todd A.</creatorcontrib><creatorcontrib>Gillies, Mark</creatorcontrib><creatorcontrib>Midena, Edoardo</creatorcontrib><creatorcontrib>Ogura, Yuichiro</creatorcontrib><title>Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies</title><title>Journal of ophthalmology</title><addtitle>J Ophthalmol</addtitle><description>Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT &lt; 400 μm and ≥400 μm. Results. At weeks 52 and 100, outcomes with intravitreal aflibercept 2q4 and 2q8 were superior to those in laser control-treated patients regardless of baseline CRT. When looked at in a binary fashion, the treatment effect of intravitreal aflibercept versus laser was not significantly better in the ≥400 μm than the &lt;400 μm group; when looked at as a continuous variable, baseline CRT seemed to have an impact on the treatment effect of intravitreal aflibercept versus laser. Conclusions. Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT &lt; 400 μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440.</description><subject>Age</subject><subject>Care and treatment</subject><subject>Clinical Study</subject><subject>Comparative analysis</subject><subject>Diabetes</subject><subject>Diabetic retinopathy</subject><subject>Lasers</subject><subject>Macular degeneration</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Studies</subject><subject>Type 2 diabetes</subject><subject>Values</subject><issn>2090-004X</issn><issn>2090-0058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks1v0zAYxiMEYlPZjTOKhISQoJu_HV-QSjeg0tAkVk3cLMd507gk9ogTEP897lq6FXHAPvjr9z62Hz1Z9hyjU4w5PyMIF2dUMIQpf5QdE6TQFCFePN7P2dej7CTGNUqNYsY5epodESULThE-zvSiuzV2yEOdvzcRWuchn4MfetPmX2BwPo3LxtlvHmLMg8-vxsGGDmLufD40kN8sbhbn0_PPF7nxVVpdL2d3q-thrBzEZ9mT2rQRTnbjJFt-uFjOP00vrz4u5rPLqRWUD1Ng0mIqCFNQG1XWzNiSyKLAhtam5BjLohYlSMJoKStRK4wAl7akCrgilE6yxVa2Cmatb3vXmf6XDsbpu43Qr7TpB2db0EzVqVhQBKVlCklTlekGBswSQ0pikta7rdbtWHZQ2a0bB6KHJ941ehV-aF4oQdILJ9nrnUAfvo8QB925aKFtjYcwRk0QI5IpkR4-yV7-ha7D2CfTE8WQFCxJsntqZdIHnK9DutduRPWMKyQ4Ukom6vQfVOoVdM4GD7VL-wcFrx4UNGDaoYmhHQcXfDwE325B24cYe6j3ZmCkNznUmxzqXQ4T_uKhgXv4T-oS8GYLNM5X5qf7TzlITIrHPY2TOVLQ37KI6kY</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Lu, Chengxing</creator><creator>Metzig, Carola</creator><creator>Katz, Todd A.</creator><creator>Gillies, Mark</creator><creator>Midena, Edoardo</creator><creator>Ogura, Yuichiro</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3132-6233</orcidid></search><sort><creationdate>20180101</creationdate><title>Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies</title><author>Lu, Chengxing ; Metzig, Carola ; Katz, Todd A. ; Gillies, Mark ; Midena, Edoardo ; Ogura, Yuichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c635t-e47c136249efa9bf4acb27881a3fab51178f6be7243b7d6f910e1bcb39e59233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Age</topic><topic>Care and treatment</topic><topic>Clinical Study</topic><topic>Comparative analysis</topic><topic>Diabetes</topic><topic>Diabetic retinopathy</topic><topic>Lasers</topic><topic>Macular degeneration</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Studies</topic><topic>Type 2 diabetes</topic><topic>Values</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Chengxing</creatorcontrib><creatorcontrib>Metzig, Carola</creatorcontrib><creatorcontrib>Katz, Todd A.</creatorcontrib><creatorcontrib>Gillies, Mark</creatorcontrib><creatorcontrib>Midena, Edoardo</creatorcontrib><creatorcontrib>Ogura, Yuichiro</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Chengxing</au><au>Metzig, Carola</au><au>Katz, Todd A.</au><au>Gillies, Mark</au><au>Midena, Edoardo</au><au>Ogura, Yuichiro</au><au>Toto, Lisa</au><au>Lisa Toto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies</atitle><jtitle>Journal of ophthalmology</jtitle><addtitle>J Ophthalmol</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>2018</volume><issue>2018</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>2090-004X</issn><eissn>2090-0058</eissn><abstract>Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods. Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed. We compared visual and anatomical outcomes in subgroups of patients with baseline CRT &lt; 400 μm and ≥400 μm. Results. At weeks 52 and 100, outcomes with intravitreal aflibercept 2q4 and 2q8 were superior to those in laser control-treated patients regardless of baseline CRT. When looked at in a binary fashion, the treatment effect of intravitreal aflibercept versus laser was not significantly better in the ≥400 μm than the &lt;400 μm group; when looked at as a continuous variable, baseline CRT seemed to have an impact on the treatment effect of intravitreal aflibercept versus laser. Conclusions. Post hoc analyses of VIVID-DME and VISTA-DME demonstrated the benefits of intravitreal aflibercept treatment in DME patients with baseline CRT &lt; 400 μm and ≥400 μm. This trial is registered with NCT01331681 and NCT01363440.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>29785301</pmid><doi>10.1155/2018/3640135</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3132-6233</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-004X
ispartof Journal of ophthalmology, 2018-01, Vol.2018 (2018), p.1-9
issn 2090-004X
2090-0058
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_49f10e630ebc4907adbab54e4c2a2b2a
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Open Access: Wiley-Blackwell Open Access Journals; PubMed Central
subjects Age
Care and treatment
Clinical Study
Comparative analysis
Diabetes
Diabetic retinopathy
Lasers
Macular degeneration
Patient outcomes
Patients
Studies
Type 2 diabetes
Values
title Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A45%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Baseline%20Central%20Retinal%20Thickness%20on%20Outcomes%20in%20the%20VIVID-DME%20and%20VISTA-DME%20Studies&rft.jtitle=Journal%20of%20ophthalmology&rft.au=Lu,%20Chengxing&rft.date=2018-01-01&rft.volume=2018&rft.issue=2018&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=2090-004X&rft.eissn=2090-0058&rft_id=info:doi/10.1155/2018/3640135&rft_dat=%3Cgale_doaj_%3EA590650997%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c635t-e47c136249efa9bf4acb27881a3fab51178f6be7243b7d6f910e1bcb39e59233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2407648964&rft_id=info:pmid/29785301&rft_galeid=A590650997&rfr_iscdi=true